A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 18,338 shares of INCY stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,338
Previous 28,483 35.62%
Holding current value
$1.27 Million
Previous $1.73 Million 29.78%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$57.33 - $68.61 $581,612 - $696,048
-10,145 Reduced 35.62%
18,338 $1.21 Million
Q2 2024

Jul 19, 2024

BUY
$51.18 - $63.75 $160,961 - $200,493
3,145 Added 12.41%
28,483 $1.73 Million
Q1 2024

Apr 22, 2024

BUY
$56.55 - $66.59 $127,689 - $150,360
2,258 Added 9.78%
25,338 $1.44 Million
Q4 2023

Jan 16, 2024

SELL
$52.16 - $64.19 $105,206 - $129,471
-2,017 Reduced 8.04%
23,080 $1.45 Million
Q3 2023

Oct 24, 2023

BUY
$57.77 - $65.93 $726,515 - $829,135
12,576 Added 100.44%
25,097 $1.45 Million
Q2 2023

Jul 25, 2023

BUY
$60.95 - $75.51 $77,528 - $96,048
1,272 Added 11.31%
12,521 $779,000
Q1 2023

Apr 14, 2023

SELL
$70.23 - $86.01 $357,962 - $438,392
-5,097 Reduced 31.18%
11,249 $812,000
Q4 2022

Feb 08, 2023

SELL
$67.18 - $84.11 $698,604 - $874,659
-10,399 Reduced 38.88%
16,346 $1.31 Million
Q3 2022

Oct 25, 2022

SELL
$66.18 - $82.86 $275,242 - $344,614
-4,159 Reduced 13.46%
26,745 $1.78 Million
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $13,566 - $17,051
205 Added 0.67%
30,904 $2.35 Million
Q1 2022

May 11, 2022

BUY
$66.02 - $79.71 $185,648 - $224,144
2,812 Added 10.08%
30,699 $2.44 Million
Q4 2021

Feb 08, 2022

SELL
$63.34 - $74.11 $180,202 - $210,842
-2,845 Reduced 9.26%
27,887 $2.05 Million
Q3 2021

Nov 02, 2021

BUY
$68.67 - $84.02 $56,309 - $68,896
820 Added 2.74%
30,732 $2.11 Million
Q2 2021

Aug 11, 2021

BUY
$79.87 - $87.53 $207,182 - $227,052
2,594 Added 9.5%
29,912 $2.52 Million
Q1 2021

May 14, 2021

BUY
$76.02 - $100.5 $344,598 - $455,566
4,533 Added 19.89%
27,318 $2.22 Million
Q4 2020

Feb 12, 2021

BUY
$80.74 - $97.7 $12,918 - $15,632
160 Added 0.71%
22,785 $1.98 Million
Q3 2020

Nov 04, 2020

BUY
$85.07 - $109.69 $28,498 - $36,746
335 Added 1.5%
22,625 $2.03 Million
Q2 2020

Jul 17, 2020

SELL
$74.18 - $108.93 $250,283 - $367,529
-3,374 Reduced 13.15%
22,290 $2.32 Million
Q1 2020

Apr 21, 2020

SELL
$63.18 - $85.97 $2.03 Million - $2.76 Million
-32,112 Reduced 55.58%
25,664 $1.88 Million
Q4 2019

Feb 12, 2020

SELL
$73.04 - $95.72 $9.9 Million - $13 Million
-135,584 Reduced 70.12%
57,776 $5.05 Million
Q3 2019

Nov 07, 2019

SELL
$72.82 - $86.52 $431,385 - $512,544
-5,924 Reduced 2.97%
193,360 $14.4 Million
Q2 2019

Aug 06, 2019

BUY
$73.52 - $88.7 $886,504 - $1.07 Million
12,058 Added 6.44%
199,284 $16.9 Million
Q1 2019

May 06, 2019

BUY
$63.56 - $88.17 $2.88 Million - $3.99 Million
45,266 Added 31.89%
187,226 $16.1 Million
Q4 2018

Feb 11, 2019

BUY
$58.5 - $69.94 $8.12 Million - $9.71 Million
138,821 Added 4422.46%
141,960 $9.03 Million
Q3 2018

Nov 14, 2018

SELL
$61.75 - $74.23 $66,443 - $79,871
-1,076 Reduced 25.53%
3,139 $217,000
Q2 2018

Jul 30, 2018

SELL
$60.85 - $83.98 $208,046 - $287,127
-3,419 Reduced 44.79%
4,215 $282,000
Q1 2018

Apr 16, 2018

BUY
$83.06 - $100.98 $456,165 - $554,582
5,492 Added 256.4%
7,634 $636,000
Q4 2017

Feb 09, 2018

SELL
$93.56 - $116.6 $24,512 - $30,549
-262 Reduced 10.9%
2,142 $203,000
Q3 2017

Oct 26, 2017

SELL
$109.15 - $138.27 $102,601 - $129,973
-940 Reduced 28.11%
2,404 $281,000
Q2 2017

Aug 15, 2017

BUY
N/A
3,344
3,344 $421,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.4B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.